The chemical, genetic and immunological basis of idiosyncratic drug-induced liver injury

Human and Experimental Toxicology

Volumn 34, Issue 12, 2015, Pages 1310-1317

  Tailor, A ^a   Faulkner, L ^a   Naisbitt, D J ^a   Park, B K ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

adduct; Dili; Idiosyncratic drug induced liver injury; pharmacogenomics

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; CHEMICALLY REACTIVE DRUG METABOLITE; DRUG METABOLITE; FLUCLOXACILLIN; ISONIAZID; UNCLASSIFIED DRUG; DRUG;

ADAPTIVE IMMUNITY; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; HUMAN; IDIOSYNCRATIC DRUG INDUCED LIVER INJURY; METABOLITE; NONHUMAN; PRIORITY JOURNAL; REVIEW; TOXIC HEPATITIS; ANIMAL; CHEMICAL AND DRUG INDUCED LIVER INJURY; GENETICS; IMMUNOLOGY; METABOLISM;

AMOXICILLIN-POTASSIUM CLAVULANATE COMBINATION; ANIMALS; CHEMICAL AND DRUG INDUCED LIVER INJURY; FLOXACILLIN; HUMANS; ISONIAZID; PHARMACEUTICAL PREPARATIONS;

EID: 84948694532     PISSN: 09603271     EISSN: 14770903     Source Type: Journal    
DOI: 10.1177/0960327115606529     Document Type: Review

References (85)

1. Bell LN, Chalasani N,. Epidemiology of idiosyncratic drug-induced liver injury. Semin Liver Dis 2009; 29: 337-347.
2. Kaplowitz N,. Drug-induced liver disorders: implications for drug development and regulation. Drug Saf 2001; 24: 483-490.
3. Aithal GP, Watkins PB, Andrade RJ, et al. Case definition and phenotype standardization in drug-induced liver injury. Clin Pharmacol Ther 2011; 89: 806-815.
4. Molleston JP, Fontana RJ, Lopez MJ, et al. Characteristics of idiosyncratic drug-induced liver injury in children: results from the DILIN prospective study. J Pediatr Gastroenterol Nutr 2011; 53: 182-189.
5. Garibaldi RA, Drusin RE, Ferebee SH, et al. Isoniazid-associated hepatitis. Report of an outbreak. Am Rev Respir Dis 1972; 106: 357-365.
6. Beraldo DO, Melo JF, Bonfim AV, et al. Acute cholestatic hepatitis caused by amoxicillin/clavulanate. World J Gastroenterol 2013; 19: 8789-8792.
7. Urban TJ, Shen Y, Stolz A, et al. Limited contribution of common genetic variants to risk for liver injury due to a variety of drugs. Pharmacogenet Genomics 2012; 22: 784-795.
8. Boelsterli UA,. Diclofenac-induced liver injury: a paradigm of idiosyncratic drug toxicity. Toxicol Appl Pharmacol 2003; 192: 307-322.
9. Daly AK, Donaldson PT, Bhatnagar P, et al. HLA-B∗5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin. Nat Genet 2009; 41: 816-819.
10. Monshi MM, Faulkner L, Gibson A, et al. Human leukocyte antigen (HLA)-B∗57:01-restricted activation of drug-specific T cells provides the immunological basis for flucloxacillin-induced liver injury. Hepatology 2013; 57: 727-739.
11. O'Donohue J, Oien KA, Donaldson P, et al. Co-amoxiclav jaundice: clinical and histological features and HLA class II association. Gut 2000; 47: 717-720.
12. Schnyder B, Burkhart C, Schnyder-Frutig K, et al. Recognition of sulfamethoxazole and its reactive metabolites by drug-specific CD4+ T cells from allergic individuals. J Immunol 2000; 164: 6647-6654.
13. Hanzlik RP, Koen YM, Fang J,. Bioinformatic analysis of 302 reactive metabolite target proteins. Which ones are important for cell death? Toxicol Sci 2013; 135: 390-401.
14. West AP, Shadel GS, Ghosh S,. Mitochondria in innate immune responses. Nat Rev Immunol 2011; 11: 389-402.
15. Nguyen T, Yang CS, Pickett CB,. The pathways and molecular mechanisms regulating Nrf2 activation in response to chemical stress. Free Radic Biol Med 2004; 37: 433-441.
16. Daly A,. Drug-induced liver injury: past, present and future. Pharmacogenomics 2010; 11: 607-611.
17. Liu YC, Chen Z, Neller MA, et al. A molecular basis for the interplay between T cells, viral mutants, and human leukocyte antigen micropolymorphism. J Biol Chem 2014; 289: 16688-16698.
18. Levy M,. Role of viral infections in the induction of adverse drug reactions. Drug Saf 1997; 16: 1-8.
19. Fredriksson L, Wink S, Herpers B, et al. Drug-induced endoplasmic reticulum and oxidative stress responses independently sensitize toward TNFα-mediated hepatotoxicity. Toxicol Sci 2014; 140: 144-159.
20. Park BK, Boobis A, Clarke S, et al. Managing the challenge of chemically reactive metabolites in drug development. Nat Rev Drug Discov 2011; 10: 292-306.
21. Watkins PB, Seligman PJ, Pears JS, et al. Using controlled clinical trials to learn more about acute drug-induced liver injury. Hepatology 2008; 48: 1680-1689.
22. Dear GJ, Beaumont C, Roberts A, et al. Approaches for the rapid identification of drug metabolites in early clinical studies. Bioanalysis 2011; 3: 197-213.
23. Stachulski AV, Baillie TA, Kevin Park B, et al. The generation, detection, and effects of reactive drug metabolites. Med Res Rev 2013; 33: 985-1080.
24. Masubuchi Y, Nakayama J, Sadakata Y,. Protective effects of exogenous glutathione and related thiol compounds against drug-induced liver injury. Biol Pharm Bull 2011; 34: 366-370.
25. Dawson S, Stahl S, Paul N, et al. In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans. Drug Metab Dispos 2012; 40: 130-138.
26. Aleo MD, Luo Y, Swiss R, et al. Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump. Hepatology 2014; 1015-1022.
27. Reasor MJ, Hastings KL, Ulrich RG,. Drug-induced phospholipidosis: issues and future directions. Expert Opin Drug Saf 2006; 5: 567-583.
28. Perez MJ, Britz O,. Bile-acid-induced cell injury and protection. World J Gastroenterol 2009; 15: 1677-1689.
29. Usui T, Mise M, Hashizume T, et al. Evaluation of the potential for drug-induced liver injury based on in vitro covalent binding to human liver proteins. Pharmacology 2009; 37: 2383-2392.
30. Li AP,. A review of the common properties of drugs with idiosyncratic hepatotoxicity and the 'multiple determinant hypothesis' for the manifestation of idiosyncratic drug toxicity. Chem Biol Interact 2002; 142: 7-23.
31. Lucena MI, Molokhia M, Shen Y, et al. Susceptibility to amoxicillin-clavulanate-induced liver injury is influenced by multiple HLA class I and II alleles BASIC AND. Gastroenterology 2011; 338-347.
32. Hautekeete ML, Horsmans Y, Van Waeyenberge C, et al. HLA association of amoxicillin-clavulanate-induced hepatitis. Gastroenterology 1999; 117: 1181-1186.
33. Stephens C, López-Nevot MÁ Ruiz-Cabello F, et al. HLA alleles influence the clinical signature of amoxicillin-clavulanate hepatotoxicity. PLoS One 2013; 8: e68111.
34. Donaldson PT, Daly AK, Henderson J, et al. Human leucocyte antigen class II genotype in susceptibility and resistance to co-amoxiclav-induced liver injury. J Hepatol 2010; 53: 1049-1053.
35. Daly AK, Aithal GP, Leathart JBS, et al. Genetic susceptibility to diclofenac-induced hepatotoxicity: contribution of UGT2B7, CYP2C8, and ABCC2 genotypes. Gastroenterology 2007; 132: 272-281.
36. Huang YS, Chern H Der, Su WJ, et al. Cytochrome P450 2E1 genotype and the susceptibility to antituberculosis drug-induced hepatitis. Hepatology 2003; 37: 924-930.
37. Huang Y, Chern H, WJS, et al. Polymorphism of the N-acetyltransferase 2 gene as a susceptibility risk factor for antituberculosis drug-induced hepatitis. Hepatology 2002; 35: 883-889.
38. Roy B, Chowdhury A, Kundu S, et al. Increased risk of antituberculosis drug-induced hepatotoxicity in individuals with glutathione S-transferase M1 'null' mutation. J Gastroenterol Hepatol 2001; 16: 1033-1037.
39. Huang Y-S, Su W-J, Huang Y-H, et al. Genetic polymorphisms of manganese superoxide dismutase, NAD(P)H: quinone oxidoreductase, glutathione S-transferase M1 and T1, and the susceptibility to drug-induced liver injury. J Hepatol 2007; 47: 128-134.
40. Sharma SK, Balamurugan A, Saha PK, et al. Evaluation of clinical and immunogenetic risk factors for the development of hepatotoxicity during antituberculosis treatment. Am J Respir Crit Care Med 2002; 166: 916-919.
41. Spraggs CF, Budde LR, Briley LP, et al. HLA-DQA1∗02:01 is a major risk factor for lapatinib-induced hepatotoxicity in women with advanced breast cancer. J Clin Oncol 2011; 29: 667-673.
42. Parham LR, Briley LP, Li L, et al. Comprehensive genome-wide evaluation of lapatinib-induced liver injury yields a single genetic signal centered on known risk allele HLA-DRB1∗07:01. Pharmacogenomics J. Epub ahead of print 19 May 2015. DOI: 10.1038/tpj.2015.40.
43. Singer JB, Lewitzky S, Leroy E, et al. A genome-wide study identifies HLA alleles associated with lumiracoxib-related liver injury. Nat Genet 2010; 42: 711-714.
44. Haas DW, Bartlett JA, Andersen JW, et al. Pharmacogenetics of nevirapine-associated hepatotoxicity: an adult AIDS clinical trials group collaboration. Clin Infect Dis 2006; 43: 783-786.
45. Ostrov DA, Grant BJ, Pompeu YA, et al. Drug hypersensitivity caused by alteration of the MHC-presented self-peptide repertoire. Proceedings of the National Academy of Sciences 2012; 109: 9959-9964.
46. Phillips E, Bartlett JA, Sanne I, et al. Associations between HLA-DRB1∗0102, HLA-B∗5801, and hepatotoxicity during initiation of nevirapine-containing regimens in South Africa. J Acquir Immune Defic Syndr 2013; 62: 55-57.
47. Martin AM, Nolan D, James I, et al. Predisposition to nevirapine hypersensitivity associated with HLA-DRB1∗0101 and abrogated by low CD4 T-cell counts. AIDS 2005; 19: 97-99.
48. Hirata K, Takagi H, Yamamoto M, et al. Ticlopidine-induced hepatotoxicity is associated with specific human leukocyte antigen genomic subtypes in Japanese patients: a preliminary case-control study. Pharmacogenomics J 2008; 8: 29-33.
49. Lucena MI, Andrade RJ, Martínez C, et al. Glutathione S-transferase m1 and t1 null genotypes increase susceptibility to idiosyncratic drug-induced liver injury. Hepatology 2008; 48: 588-596.
50. Kindmark A, Jawaid A, Harbron CG, et al. Genome-wide pharmacogenetic investigation of a hepatic adverse event without clinical signs of immunopathology suggests an underlying immune pathogenesis. Pharmacogenomics J 2008; 8: 186-195.
51. Kim S, Kim S, Lee J, et al. Superoxide dismutase gene (SOD1, SOD2, and SOD3) polymorphisms and antituberculosis drug-induced hepatitis subject characteristics. Allergy Asthma Immunol Res 2015; 7: 88-91.
52. Naisbitt DJ, Sanderson LS, Meng X, et al. Investigation of the immunogenicity of diclofenac and diclofenac metabolites. Toxicol Lett 2007; 168: 45-50.
53. Kaniwa N, Saito Y,. Pharmacogenomics of severe cutaneous adverse reactions and drug-induced liver injury. J Hum Genet 2013; 58: 317-326.
54. Norcross MA, Luo S, Lu L, et al. Abacavir induces loading of novel self-peptides into HLA-B∗57: 01: an autoimmune model for HLA-associated drug hypersensitivity. AIDS 2012; 26: F21-F29.
55. Mallal S, Phillips E, Carosi G, et al. HLA-B∗5701 screening for hypersensitivity to abacavir. N Engl J Med 2008; 358: 568-579.
56. Tajiri K, Shimizu Y,. Immunological aspects of drug-induced liver injury. World J Immunol 2014; 4: 26-33.
57. Ju C, Reilly T,. Role of immune reactions in drug-induced liver injury (DILI). Drug Metab Rev 2012; 44: 107-115.
58. Mennicke M, Zawodniak A, Keller M, et al. Fulminant liver failure after vancomycin in a sulfasalazine-induced DRESS syndrome: Fatal recurrence after liver transplantation: Case report. Am J Transplant 2009; 9: 2197-2202.
59. Wuillemin N, Terracciano L, Beltraminelli H, et al. T cells infiltrate the liver and kill hepatocytes in HLA-B ∗57:01-associated floxacillin-induced liver injury. Am J Pathol 2014; 184: 1677-1682.
60. Bowen DG, Zen M, Holz L, et al. The site of primary T cell activation is a determinant of the balance between intrahepatic tolerance and immunity. J Clin Invest 2004; 114: 701-712.
61. El-ghaiesh S, Monshi MM, Whitaker P, et al. Characterization of the antigen specificity of T-cell clones from piperacillin-hypersensitive patients with cystic fibrosis. J Pharmacol Exp Ther 2012; 341: 597-610.
62. Matzinger P,. Tolerance, danger, and the extended family. Annu Rev Immunol 1994; 12: 991-1045.
63. Thomson AW, Knolle PA,. Antigen-presenting cell function in the tolerogenic liver environment. Nat Rev Immunol 2010; 10: 753-766.
64. Brenner C, Galluzzi L, Kepp O, et al. Decoding cell death signals in liver inflammation. J Hepatol 2013; 59: 583-594.
65. Weltzien HU, Moulon C, Martin S, et al. T cell immune responses to haptens. Structural models for allergic and autoimmune reactions. Toxicology 1996; 107: 141-151.
66. Aithal GP,. Pharmacogenetic testing in idiosyncratic drug-induced liver injury (DILI): current role in clinical practice. Liver Int 2015; 35: 1801-1808.
67. Azuma J, Ohno M, Kubota R, et al. NAT2 genotype guided regimen reduces isoniazid-induced liver injury and early treatment failure in the 6-month four-drug standard treatment of tuberculosis: a randomized controlled trial for pharmacogenetics-based therapy. Eur J Clin Pharmacol 2013; 69: 1091-1101.
68. Timbrell JA, Mitchell JR, Snodgrass WR, et al. Isoniazid hepatoxicity: the relationship between covalent binding and metabolism in vivo. J Pharmacol Exp Ther 1980; 213: 364-369.
69. Metushi IG, Cai P, Zhu X, et al. A fresh look at the mechanism of isoniazid-induced hepatotoxicity. Clin Pharmacol Ther 2011; 89: 911-914.
70. Maria VA, Victorino RM,. Diagnostic value of specific T cell reactivity to drugs in 95 cases of drug induced liver injury. Gut 1997; 41: 534-540.
71. Warrington RJ, McPhilips-Feener S, Rutherford WJ,. The predictive value of the lymphocyte transformation test in isoniazid-associated hepatitis. Clin Allergy 1982; 12: 217-222.
72. Warrington RJ, Tse KS, Gorski BA, et al. Evaluation of isoniazid-associated hepatitis by immunological tests. Clin Exp Immunol 1978; 32: 97-104.
73. Metushi IG, Sanders C, Lee WM, et al. Detection of anti-isoniazid and anti-cytochrome P450 antibodies in patients with isoniazid-induced liver failure. Hepatology 2014; 59: 1084-1093.
74. Weltzien HU, Padovan E,. Molecular features of penicillin allergy. J Invest Dermatol 1998; 110: 203-206.
75. Schneider CH, De Weck AL,. A new chemical aspect of penicillin allergy: the direct reaction of penicillin with e-amino-groups. Nature 1965; 208: 57.
76. Martinez-Mir I, Ferrer JM, Palop V, et al. Are the adverse drug reactions of amoxycillin and amoxycillin-clavulanic acid similar? Pharmacoepidemiol Drug Saf 1996; 5: 247-254.
77. Kim S-H, Saide K, Farrell J, et al. Characterization of amoxicillin- and clavulanic acid-specific T cells in patients with amoxicillin-clavulanate-induced liver injury. Hepatology 2015; 62: 887-899.
78. Wuillemin N, Adam J, Fontana S, et al. HLA haplotype determines hapten or p-i T cell reactivity to flucloxacillin. J Immunol 2013; 190: 4956-4964.
79. Jenkins RE, Yaseen FS, Monshi MM, et al. β-Lactam antibiotics form distinct haptenic structures on albumin and activate drug-specific T-lymphocyte responses in multiallergic patients with cystic fibrosis. Chem Res Toxicol 2013; 26: 963-975.
80. Nattrass R, Faulkner L, Vocanson M, et al. Activation of flucloxacillin-specific CD8+ T-cells with the potential to promote hepatocyte cytotoxicity in a mouse model. Toxicol Sci 2015; 146: 146-156.
81. Carey MA, Van Pelt FN,. Immunochemical detection of flucloxacillin adduct formation in livers of treated rats. Toxicology 2005; 216: 41-48.
82. Wen B, Fitch WL,. Screening and characterization of reactive metabolites using glutathione ethyl ester in combination with Q-trap mass spectrometry. J Mass Spectrom 2009; 44: 90-100.
83. Faulkner L, Martinsson K, Santoyo-Castelazo A, et al. The development of in vitro culture methods to characterize primary T-cell responses to drugs. Toxicol Sci 2012; 127: 150-158.
84. Metushi IG, Cai P, Dervovic D, et al. Development of a novel mouse model of amodiaquine-induced liver injury with a delayed onset. J Immunotoxicol 2014; 6901: 1-14.
85. Metushi IG, Hayes MA, Uetrecht J,. Treatment of PD-1 -/- mice with amodiaquine and anti-CTLA4 leads to liver injury similar to idiosyncratic liver injury in patients. Hepatology 2015; 61: 1332-1342.